表紙:心房中隔オクルーダーデバイスの世界市場 (2021年~2028年)
市場調査レポート
商品コード
1020356

心房中隔オクルーダーデバイスの世界市場 (2021年~2028年)

Global Atrial Septal Occluder Devices Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.31円
心房中隔オクルーダーデバイスの世界市場 (2021年~2028年)
出版日: 2021年07月28日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

心房中隔閉塞器具は、特殊な心房中隔欠損症を持つ患者に使われる、植え込み式の心臓装置です。右心房や右心室の拡大を伴う心房中隔欠損症に使用され、奇異性塞栓症や左右短絡、POS (platypnea-orthodeoxia syndrome) 症候群などを予防します。

当レポートでは、世界の心房中隔オクルーダーデバイスの市場について分析し、市場規模の動向見通しや、種類別・エンドユーザー別・地域別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイルなどについて調査しております。

目次

第1章 世界の心房中隔オクルーダーデバイス市場:分析手法・範囲

第2章 世界の心房中隔オクルーダーデバイス市場:市場の定義と概要

第3章 世界の心房中隔オクルーダーデバイス市場:エグゼクティブサマリー

第4章 世界の心房中隔オクルーダーデバイス市場:市場力学

  • 市場への影響要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の心房中隔オクルーダーデバイス市場:業界分析

  • ポーターのファイブフォース分析
  • 疫学分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 世界の心房中隔オクルーダーデバイス市場:新型コロナウイルス感染症 (COVID-19) の分析

  • COVID-19の市場への影響の分析
    • 「ビフォーコロナ」/過去の市場シナリオ
    • 「ウィズコロナ」/現在の市場シナリオ
    • 「アフターコロナ」/将来の市場シナリオ
  • COVID-19流行中の価格動向
  • 需要・供給の変動域
  • 感染拡大時の市場に対する政府の取り組み
  • メーカー各社の戦略展開状況
  • 結論

第7章 心房中隔オクルーダーデバイス市場:種類別

  • イントロダクション
    • 市場規模の分析と対前年成長率 (YoY):種類別
    • 市場求心力指数:種類別
  • 心房中隔欠損症デバイス
    • イントロダクション
    • 市場規模 (金額ベース、2018年~2028年)・対前年成長率 (YoY) (2020年~2028年)
  • 心室中隔欠損症デバイス

第8章 心房中隔オクルーダーデバイス市場:エンドユーザー別

  • イントロダクション
  • 病院・外来手術センター
  • 専門クリニック
  • その他

第9章 心房中隔オクルーダーデバイス市場:地域別

  • イントロダクション
    • 市場規模 (金額ベース、2018年~2028年)・対前年成長率 (YoY) (2020年~2028年):地域別
    • 市場求心力指数:地域別
  • 北米
    • イントロダクション
    • 域内市場の固有の動向
    • 市場規模・対前年成長率 (YoY):種類別
    • 市場規模・対前年成長率 (YoY):エンドユーザー別
    • 市場規模・対前年成長率 (YoY):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第10章 世界の心房中隔オクルーダーデバイス市場:競合情勢

  • 主な動向と戦略
  • 企業シェア分析
  • 製品の相互比較
  • 注目すべき企業の一覧
  • 破壊的技術を有する企業の一覧
  • スタートアップ企業の一覧

第11章 心房中隔オクルーダーデバイス市場:企業プロファイル

  • W. L. Gore & Associates, Inc.
    • 企業概要
    • 製品のポートフォリオ/概略
    • 近年の動向
    • 主な財務指標
  • Abbott Laboratories
  • Medtronic Plc.
  • Endologix Inc.
  • LivaNova Plc.
  • CryoLife Inc.
  • Cook Group Incorporated
  • Edwards Lifesciences Corporation
  • Lepu medical technology
  • CeraFlex

第12章 DataM Intelligenceについて

目次
Product Code: DMMD3679

Atrial Septal Occluder Devices Market. Overview

The atrial septal occluder devices market. The size was valued at US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Atrial septal occlusion devices are implantable cardiac devices used in patients with certain types of atrial septal defects. They are used in atrial septal defects with right atrial or ventricle enlargement to prevent paradoxical embolism, left-to-right shunting, and platypnea-orthodeoxia syndrome.

Atrial Septal Occluder Devices Market. Dynamics

An increase in the prevalence of stroke and technological advancements will drive the atrial septal occluder devices market in the forecast period.

Increase in the prevalence of stroke will drive the atrial septal occluder devices market

Stroke is the second leading cause of death worldwide and the main cause of long-term neurological disability in adults.

Every year, in the U.S more than 795,000 people have a stroke. About 610,000 of these are first or new strokes. Approximately 185,000 strokes-nearly 1 of 4-are in people who have had a previous stroke. About 87% of strokes are ischemic strokes, in which blood flow to the brain is blocked. Atrial septal defect or patent foramen ovale (PFO), a septal occluder device might be a good option for the people who experienced a stroke. This device may decrease the risk of stroke and allow one to stop taking blood thinners.

PFO closure along with GORE® CARDIOFORM Septal Occluder offers an advanced solution for stroke teams and their cryptogenic stroke patients. The approach to stroke prevention is proven in the Gore REDUCE Clinical Study, the only U.S. IDE trial that achieved its primary end point and showed the largest reduction in recurrent ischemic stroke in all PFO shunt sizes over medical therapy alone.

Technological advancements will drive the atrial septal occluder devices market in the forecast period

Transcatheter closure of secundum atrial septal defect (ASD), patent foramen ovale (PFO) are now widely accepted as an alternate to surgical closure. With the availability of devices and techniques, approximately 80-90% of secundum ASDs and all PFOs can be closed percutaneously. Eventhough many devices are available, the use of any particular device is primarily dictated by individual defect anatomy, device availability, long-term considerations, approval status (U.S. Food and Drug Administration approval versus C.E. mark), and physician preference.

In the U.S., the Amplatzer septal occluder (ASO) (AGA Medical Corporation, Plymouth, MN, USA) and HELEX septal occluder (W.L. Gore & Associates, Inc., Flagstaff, AZ, USA) are the only ASD closure devices which are approved by the U.S. Food and Drug Administration (FDA). A non-randomized trial in the U.S. using the ASO and the U.S. multi-center pivotal trial (using the HELEX septal occluder) both demonstrated transcatheter ASD closure to be equivalent to surgical ASD closure clinical efficacy and overall safety in patients with suitable anatomy. Though not approved in the U.S. for ASD closure, many other transcatheter occluders are approved for human use worldwide.

The complications associated with the atrial septal occluder devices will hamper the market

Atrial septal defect (ASD) is the most typical surgery performed by a cardiac surgeon in training to learn the basics of cardiopulmonary bypass. Of late, this entity is slowly slipping out of the surgeon's hands because of the percutaneous devices. ASD device closure carries a not negligible burden of complications, namely atrial fibrillation, haematoma at the puncture site, device embolization, device-related erosion, and device thrombosis.

The complications reported include cardiac perforations, device malposition or embolisation, residual shunts, vascular trauma, thrombus formation, atrioventricular valve regurgitation, atrial arrhythmias, infectious endocarditis, and sudden death. Atrial septal defect closure-related complications rarely occur many years after implantation. However, the long-term risk is not negligible, and the clinician should never drop his guard down, even in asymptomatic patients. Moreover, when dealing with deficient aortic rim, weight possible risk and benefits associated with the percutaneous technique compared to the surgical intervention.

COVID-19 Impact Analysis

During the coronavirus pandemic, the LAA closure devices industry is likely to experience a surge in the growth rate. During pandemic,the governments of various countries have taken initiatives to create awareness amongst people regarding the importance of left atrial appendage closure devices which is the major factor expected to boost the market growth in 2020. Besides, several manufacturers are stressing their product improvements to obtain a strong position and sustain in the global market in coronavirus emergencies.

In February 2020, Abbott received an approval from the U.S. Food and Drug Administration (FDA) for their newly innovated Amplatzer Amulet Left Atrial Appendage Occluder designed for A.F. patients.

Atrial Septal Occluder Devices Market. Segment Analysis

Atrial septal defect devices dominated the market

In recent years, closure of an ASD in patients with a hemodynamically significant shunt has become the standard of care. Correction of ASDs helps to prevent the development of pulmonary hypertension, cardiac arrhythmia, and heart failure. Atrial septal defect closure has become an established therapy that is performed in increasing numbers of adult patients. W.L. Gore and Associates announced its occluder device was approved by the FDA for percutaneous closure of ostium secundum atrial septal defects.

On June 4, 2019 W. L. Gore & Associates (Gore) announced the premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ostium secundum atrial septal defects (ASDs) from the U.S. Food and Drug Administration's (FDA's) . The approval from FDA was supported by data collected from the pivotal stage of the Gore ASSURED Clinical Study, which demonstrated 100 percent closure success at the six-month evaluation in patients with a successful implant.

Hospitals and Ambulatory Surgical Centers and ambulatory surgical centers will dominate the market

Patients who have or had repair of an atrial septal defect generally have a normal life. Most women can have normal, uncomplicated pregnancies. While small percentage of patients may develop pulmonary hypertension - high pressures in the lung circulation - or abnormal heart rhythms. For this reason, it is recommended that a cardiologist with interest in congenital heart disease evaluate all patients at least once during adulthood. A woman contemplating pregnancy also should be considered before conception. After that, yearly follow-up is prudent. Hence, hospitals and ambulatory surgical centers will dominate the market.

Atrial Septal Occluder Devices Market. Geographical Analysis

North America will dominate the atrial septal occluder devices market

Due to the high incidence of stroke and advanced technology, this region will see a rise in the market.Stroke is the leading cause of disability and the fifth leading cause of death in the United States. Each year, around 795,000 people in the United States experience new (610,000 people) or recurrent (185,000 people) strokes. In addition, epidemiologic studies indicate that 82-92% of strokes in the United States are ischemic.

Stroke was a leading cause of death in theU.S, killing more than 147,000 Americans in 2018.

Atrial Septal Occluder Devices Market. Competitive Landscape

Some prominent key players in this market are Abbott Laboratories, Medtronic Plc., Endologix Inc., LivaNova Plc., CryoLife Inc., Cook Group Incorporated, Edwards Lifesciences Corporation, W. L. Gore & Associates, Inc., lepu medical technology and CeraFlex

Atrial Septal Occluder Devices Market. Key Companies to Watch

W. L. Gore & Associates, Inc.

W. L. Gore & Associates is a global materials science company which is dedicated to transform industries and improve lives. Since 1958, Gore has solved many complex technical challenges in demanding environments from outer space to the world's highest peaks to the human body's inner workings. It is an American multinational manufacturing company specializing in products derived from fluoropolymers. It is a private corporation headquartered in Newark, Delaware.

Product Portfolio: W. L. Gore & Associates is a company dedicated to transforming industries and improving lives. An American multinational manufacturing company specializing in products derived from fluoropolymers.

Key Development: W. L. Gore & Associates (Gore) announced the approval of the GORE HELEX Septal Occluder with a modified catheter delivery system from the U.S. Food & Drug Administration (FDA), which is indicated for the transcatheter closure of atrial septal defect (ASD). ASD is a congenital heart defect that affects thousands of patients every year. The GORE HELEX Septal Occluder is a permanent implanted prosthesis and the first device of its kind to use ePTFE, a biocompatible material which allows tissue ingrowth to seal the defect. In addition, the catheter-based delivery system which was recently approved allows easier device deployment via standard femoral venous access, bringing the GORE HELEX Septal Occluder to the forefront of non-surgical ASD repair.

Why Purchase the Report?

  • Visualize the composition of the Atrial Septal Occluder Devices Market. Segmentation By Product Type and End-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in Atrial Septal Occluder Devices Market. by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Atrial Septal Occluder Devices Market. - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The Atrial Septal Occluder Devices Market. report would provide an access to an approx. 52 market data table, 40 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Atrial Septal Occluder Devices Market. - By Product Type

  • Atrial Septal Defect Device
  • Ventricular Septal Defect Device

Atrial Septal Occluder Devices Market. - By End-User

  • Hospitals and Ambulatory Surgical Centers
  • Specialty Clinics
  • Others

Atrial Septal Occluder Devices Market. - By Region

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa

Table of Contents

1. Atrial Septal Occluder Devices Market. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Atrial Septal Occluder Devices Market. - Market Definition and Overview

3. Atrial Septal Occluder Devices Market. - Executive Summary

  • 3.1. Market Snippet By Product Type
  • 3.2. Market Snippet by End User

4. Atrial Septal Occluder Devices Market. - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in the prevalence of stroke will drive the atrial septal occluder devices market
      • 4.1.1.2. Technological advancements will drive the atrial septal occluder devices market in the forecast period
    • 4.1.2. Restraints:
      • 4.1.2.1. The complications associated with the atrial septal occluder devices will hamper the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Atrial Septal Occluder Devices Market. - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Atrial Septal Occluder Devices Market. - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Atrial Septal Occluder Devices Market. - By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Atrial Septal Defect Device *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Ventricular Septal Defect Device

8. Atrial Septal Occluder Devices Market. - By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Hospitals and Ambulatory Surgical Centers *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Specialty Clinics
  • 8.4. Others

9. Atrial Septal Occluder Devices Market. - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Atrial Septal Occluder Devices Market. - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. List of Key Companies to Watch
  • 10.5. List of Company with disruptive technology
  • 10.6. List of Start Up Companies

11. Atrial Septal Occluder Devices Market. - Company Profiles

  • 11.1. W. L. Gore & Associates, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Abbott Laboratories
  • 11.3. Medtronic Plc.
  • 11.4. Endologix Inc.
  • 11.5. LivaNova Plc.
  • 11.6. CryoLife Inc.
  • 11.7. Cook Group Incorporated
  • 11.8. Edwards Lifesciences Corporation
  • 11.9. Lepu medical technology
  • 11.10. CeraFlex

LIST NOT EXHAUSTIVE

12. Atrial Septal Occluder Devices Market. - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us